Loading...
OTCM
GCTK
Market cap818kUSD
, Last price  
USD
Name

GlucoTrack Inc

Chart & performance

D1W1MN
OTCM:GCTK chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-27.61%
Rev. 5Y
8.45%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
0000059,775143,167611,689589,46243,488208,000000000
Net income
-19m
L-14.20%
-1,202,296-2,788,446-2,364,339-2,772,307-9,796,8532,980,426-5,842,172-5,409,737-10,328,806-6,715,420-3,516,000-2,696,000-4,067,000-4,435,000-7,097,000-22,597,000-19,388,000
CFO
-15m
L+22.02%
-1,367,837-1,916,113-2,296,989-3,217,767-3,361,645-4,565,224-5,311,830-5,895,119-4,892,277-3,899,087-3,501,000-3,769,000-3,729,000-6,558,000-12,490,000-15,240,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.

Key people

Peter Wulff
Chief Financial Officer · since 2025
Drinda Benjamin
Vice President of Marketing · since 2023
Sandie Martha
Vice President - Clinical Operations · since 2024
Mark Tapsak
Vice President of Technology · since 2022
Ted Williams
Vice President - Regulatory Affairs · since 2025
John Ballantyne
Director · since 2024
Paul Goode
President, Chief Executive Officer, Director · since 2024
Andrew Balo
Independent Director · since 2024
Victoria Carr-Brendel
Independent Director · since 2025
Erin Carter
Independent Director · since 2023
Luis Malave
Independent Director · since 2021
URL
https://glucotrack.com
IPO date
Apr 09, 2013
Employees
Domiciled in
IL
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
PO Box 432
102 Ha'Avoda Street
Ashkelon, D 7810301
IL
Previous name
Integrity Applications, Inc.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT